NEWNAN, Ga., Dec. 3 /PRNewswire/ -- CeloNova BioSciences, Inc., announced today that it has expanded the areas in which it is commercializing the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F -- a stent system that has not had any stent thrombosis in clinical studies. It is CE Marked and available for purchase throughout Europe and now some Middle Eastern countries with aggressive world-wide expansion ongoing. Concurrently, CeloNova notes that it has received regulatory approval to increase the shelf life for the stent from two years to three years.
The CATANIA(TM) Polyzene(R)-F surface treatment is an inorganic polymer that confers superior biocompatibility and lubricity to the substrates it coats. The Polyzene(R)-F treated surface is anti-inflammatory, promotes quick and complete vessel healing, reduces peri-operative and post-procedural platelet activation, and helps to prevent tissue reactions that lead to restenosis.
"After having evaluated the Polyzene(R)-F coating many years ago, it is interesting to see this concept coming back with experimental and initial clinical data quite encouraging toward prevention of stent thrombosis," said Antonio Colombo, MD, Director of the Cardiac Catheterization Laboratory at Columbus Hospital and Chief of Invasive Cardiology at San Raffaele Hospital, both in Milan, Italy, who recently added the CATANIA(TM) stent to his practice.
The 1-year data for the first-in-man (FIM) presented at the recent
Transcatheter Cardiovascular Therapeutics conference shows that at 12 months,
in an unusually complex FIM patient population, the results
|SOURCE CeloNova BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved